- Home
- SNTI vs VERI Comparison
SNTI vs VERI Comparison
Compare SNTI & VERI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- VERI
- Stock Information
- Founded
- SNTI 2016
- VERI 2014
- Country
- SNTI United States
- VERI United States
- Employees
- SNTI N/A
- VERI N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- VERI EDP Services
- Sector
- SNTI Health Care
- VERI Technology
- Exchange
- SNTI Nasdaq
- VERI Nasdaq
- Market Cap
- SNTI 85.3M
- VERI 91.5M
- IPO Year
- SNTI N/A
- VERI 2017
- Fundamental
- Price
- SNTI $3.10
- VERI $1.84
- Analyst Decision
- SNTI Strong Buy
- VERI Strong Buy
- Analyst Count
- SNTI 1
- VERI 3
- Target Price
- SNTI $12.00
- VERI $4.17
- AVG Volume (30 Days)
- SNTI 225.5K
- VERI 484.7K
- Earning Date
- SNTI 05-06-2025
- VERI 05-08-2025
- Dividend Yield
- SNTI N/A
- VERI N/A
- EPS Growth
- SNTI N/A
- VERI N/A
- EPS
- SNTI N/A
- VERI N/A
- Revenue
- SNTI N/A
- VERI $90,937,000.00
- Revenue This Year
- SNTI N/A
- VERI $23.41
- Revenue Next Year
- SNTI N/A
- VERI $26.79
- P/E Ratio
- SNTI N/A
- VERI N/A
- Revenue Growth
- SNTI N/A
- VERI N/A
- 52 Week Low
- SNTI $1.52
- VERI $1.86
- 52 Week High
- SNTI $16.94
- VERI $5.64
- Technical
- Relative Strength Index (RSI)
- SNTI 41.06
- VERI 36.94
- Support Level
- SNTI $3.10
- VERI $1.77
- Resistance Level
- SNTI $3.61
- VERI $2.05
- Average True Range (ATR)
- SNTI 0.40
- VERI 0.12
- MACD
- SNTI -0.07
- VERI -0.01
- Stochastic Oscillator
- SNTI 9.50
- VERI 15.25
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel, and India.